Journey Medical CEO to speak at investor conferences in September 2025.
ByAinvest
Wednesday, Sep 3, 2025 8:36 am ET1min read
DERM--
Journey Medical markets eight branded FDA-approved prescription drugs for treating common skin conditions. The company, located in Scottsdale, Arizona, was founded by Fortress Biotech, Inc. (Nasdaq: FBIO) and is known for its efficient sales and marketing model. The company's products include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend, as well as two authorized generic products, sulconazole nitrate cream and solution, and doxycycline hyclate immediate release 50mg tablets.
The participation in these conferences is an opportunity for investors and financial professionals to gain insights into the company's strategies, market position, and future growth prospects. Maraoui's involvement underscores Journey Medical's commitment to transparency and engagement with its stakeholders.
References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143630/0/en/Journey-Medical-Corporation-to-Participate-in-September-2025-Investor-Conferences.html
[2] https://www.stocktitan.net/news/DERM/journey-medical-corporation-to-participate-in-september-2025-elhqiebx3t5p.html
[3] https://ir.journeymedicalcorp.com/new-events/press-releases/detail/95/journey-medical-corporation-to-participate-in-september
[4] https://www.marketscreener.com/news/journey-medical-corp-may-sell-3-750-000-shares-of-common-stock-ce7c50dcda8df121
Journey Medical Corporation announced that Claude Maraoui, CEO, will participate in two investor conferences in September 2025. Maraoui will participate in a fireside chat and 1x1 meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 and at the Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference on September 11. Journey Medical is a commercial-stage pharmaceutical company focused on dermatological conditions.
Journey Medical Corporation (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on dermatological conditions, has announced that Claude Maraoui, Co-Founder, President, and Chief Executive Officer, will participate in two September 2025 investor conferences. Maraoui will engage in a fireside chat and 1x1 meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, and at the Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference on September 11, both in New York City.Journey Medical markets eight branded FDA-approved prescription drugs for treating common skin conditions. The company, located in Scottsdale, Arizona, was founded by Fortress Biotech, Inc. (Nasdaq: FBIO) and is known for its efficient sales and marketing model. The company's products include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend, as well as two authorized generic products, sulconazole nitrate cream and solution, and doxycycline hyclate immediate release 50mg tablets.
The participation in these conferences is an opportunity for investors and financial professionals to gain insights into the company's strategies, market position, and future growth prospects. Maraoui's involvement underscores Journey Medical's commitment to transparency and engagement with its stakeholders.
References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143630/0/en/Journey-Medical-Corporation-to-Participate-in-September-2025-Investor-Conferences.html
[2] https://www.stocktitan.net/news/DERM/journey-medical-corporation-to-participate-in-september-2025-elhqiebx3t5p.html
[3] https://ir.journeymedicalcorp.com/new-events/press-releases/detail/95/journey-medical-corporation-to-participate-in-september
[4] https://www.marketscreener.com/news/journey-medical-corp-may-sell-3-750-000-shares-of-common-stock-ce7c50dcda8df121
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet